Imeik Technology Investment Quality Review (300896.SZ)
Data timestamp: 2026-07-24 22:04 UTC
Quality score: 72/100
Valuation position: current price/base fair value (FV) 1.49
Final signal: WATCHLIST
Core Conclusion
Imeik is a WATCHLIST name. The company has attractive medical-aesthetics cash-flow traits, but quality is below the 75 threshold used for upgrades and the current price is well above base FV.
- Quality: 72/100. Evidence comes from five-year revenue, FCF, ROE/ROIC, and balance sheet, but disclosure boundaries and price safety constrain the signal.
- Price: current price is CNY98.60 and market value is about CNY29.84 billion. Conservative/base FV is CNY53.46/CNY66.07 per share.
Business Breakdown
Medical-aesthetics product revenue was CNY1.45 billion in 2021, CNY1.94 billion in 2022, CNY2.87 billion in 2023, CNY3.03 billion in 2024, and CNY2.45 billion in 2025, a 14.1% CAGR. Segment margin/profit was not disclosed. Latest annual FCF was CNY1.27 billion.
Quality Gate
The quality score is 72/100, a good-company watch rather than an excellent rating. Five-year average FCF/Net Income was 0.91 and OCF/Net Income was 1.00. Latest net cash/debt was CNY0.97 billion. The report requires continued checks on pricing, product concentration, regulatory risk, and formal governance evidence.
Financial Audit
The valuation uses fiscal 2025-2021 in CNY. Latest cash was CNY1.23 billion, current financial assets CNY0.02 billion, non-current financial assets CNY0.17 billion, and debt CNY0.25 billion. If goodwill, receivables, inventory, or financial-asset composition changes materially, official filings should be reviewed first.
Valuation
CNY 10Y government yield was 1.7282% from ChinaBond on 2026-07-24.
| Scenario | Core Assumption | Multiple Basis | Fair Market Value | FV/Share | Price/FV | Weight | Next Check |
|---|---|---|---|---|---|---|---|
| Conservative | Normalized FCF CNY1.27bn with heavier haircut | g 1.0%, 12.0x | CNY16.18bn | CNY53.46 | 1.84 | 30% | Next revenue, FCF, capital allocation |
| Base | Normalized FCF CNY1.27bn continues | g 2.0%, 15.0x | CNY19.99bn | CNY66.07 | 1.49 | 50% | Next revenue, FCF, capital allocation |
| Optimistic | Quality rerating without exceeding cap | g 3.0%, 17.0x | CNY22.53bn | CNY74.47 | 1.32 | 20% | Next revenue, FCF, capital allocation |
Balance-sheet bridge is CNY0.93 billion. Price/base FV of 1.49 fails the 2x gate.
Buy And Monitor
Current action is watch. Upgrade requires price/base FV below 0.70, quality score at least 75, and stronger mispricing evidence. Track revenue, FCF/Net Income, ROIC, net cash/debt, product demand, regulatory changes, dividends, buybacks, and governance.
Risks
Risks include product concentration, channel/regulatory pressure, FCF repeatability, financial-asset haircuts, and capital allocation. A sustained FCF/Net Income drop, net-debt increase, impairment, or dilutive shareholder action would lower FV and signal.
Research only. Not personalized investment advice.
Sources
Market and financial baseline data came from public quote and financial platforms. Official disclosure venues are required for annual reports, dividends, buybacks, governance, related parties, incentives, and risk evidence. Risk-free rate: ChinaBond, 2026-07-24.